Results 121 to 130 of about 157,234 (246)

Early diagnosis of Alzheimer's disease: update on combining genetic and brain-imaging measures. [PDF]

, 2000
Diagnosis of Alzheimer's disease is often missed or delayed in clinical practice; thus, methods to improve early detection would provide opportunities for early intervention, symptomatic treatment, and improved patient function.
Small, GW
core   +1 more source

What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review [PDF]

, 2017
Distinguishing dementia subtypes can be difficult due to similarities in clinical presentation. There is increasing interest in discrete gait characteristics as markers to aid diagnostic algorithms in dementia.
Galna, Brook, Mc Ardle, Ríona, Morris, Rosie, Rochester, Lynn, Thomas, Alan J., Wilson, Joanna   +5 more
core   +2 more sources

Additional file 2: of Beneficial effects of curtailing immune susceptibility in an Alzheimerâ s disease model

, 2019
Figure S2. Effects of the treatment with an anti-TNFSF10 monoclonal antibody on the expression of FoxP3, as well as the anti-inflammatory protein IL-10 in the hippocampus of 3xTg-AD mice. Immunofluorescence by confocal microscopy of hippocampi for IL-10 and FoxP3 expression and co-localization from the same animal groups as above (merge column; DAPIâ ...
Benedetto, Giulia Di, Burgaletto, Chiara, Carta, Anna, Saccone, Salvatore, Lempereur, Laurence, Mulas, Giovanna, Loreto, Carla, Bernardini, Renato, Cantarella, Giuseppina   +8 more
openaire   +1 more source

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source

Additional file 1: of Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimerâ s disease

, 2019
Table S1. Participantsâ family mutations. (DOCX 17 kb)
Weston, Philip, Poole, Teresa, O’Connor, Antoinette, Heslegrave, Amanda, Ryan, Natalie, Liang, Yuying, Druyeh, Ronald, Mead, Simon, Blennow, Kaj, Schott, Jonathan, Frost, Chris, Zetterberg, Henrik, Fox, Nick   +12 more
openaire   +1 more source

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Accessing brain magnetic resonance imaging (MRI) can be challenging, especially for underserved patients, which may lead to disparities in neurological diagnosis. Method This mixed‐methods study enrolled adults with one of four neurological disorders: mild cognitive impairment or dementia of the Alzheimer type, multiple sclerosis ...
Maya L. Mastick, Nomin Enkhtsetseg, Joseph Sadok, Matheus Mochetti, Annabel Sorby Adams, Jennifer Guo, Cristina Trapaga Hacker, Isabella Gomez Hjerthen, Seungwon Lee, Siddharth Satish, Andrew S. Ham, Justin Hill, Denis Balaban, Kevin Kyle, Rebecca L. Gillani, Marcelo Matiello, Aleksandar Videnovic, Eric C. Klawiter, W. Taylor Kimberly, Farrah J. Mateen   +19 more
wiley   +1 more source

Additional file 1: of Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimerâ s disease

, 2017
Cost-effectiveness of cerebrospinal biomarkers for Alzheimerâ s diagnosis: supplemental Methods, Results, figures and tables as referenced in the text. (DOCX 91 kb)
Lee, Spencer, Sposato, Luciano, Hachinski, Vladimir, Cipriano, Lauren   +3 more
openaire   +1 more source

Nutraceuticals in cognitive impairment and Alzheimer’s disease

Frontiers in Pharmacology, 2014
Several chemical substances belonging to classes of natural dietary origin display protective properties against some age-related diseases including neurodegenerative ones, particularly Alzheimer's disease (AD). These compounds, known as nutraceuticals, differ structurally, act therefore at different biochemical and metabolic levels and have shown ...
Mecocci, P., Tinarelli, C., Schulz, R. J., Polidori, M. C.   +3 more
openaire   +3 more sources

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

In silico studies on potential binding sites of amyloid inhibitor compounds on amyloid beta peptide [PDF]

, 2012
The formation of structurally similar insoluble fibrillar protein aggregates, called amyloids, is known to cause several neuronal and non-neuronal degenerative diseases such as Alzheimer‟s disease, Parkinson‟s disease, Huntington‟s disease and Diabetes ...
Rudra, Sumon
core